目的 研究芪血通絡片聯(lián)合依達拉奉注射液治療急性腦梗死的臨床療效。方法 選取2019年1月—2020年1月廣元市第三人民醫(yī)院收治的100例急性腦梗死患者，將所有患者隨機分為對照組和治療組，每組各50例。對照組患者靜脈滴注依達拉奉注射液，30 mL/次，2次/d。治療組在對照組基礎上口服芪血通絡片，4片/次，3次/d。兩組患者持續(xù)治療14 d。觀察兩組患者臨床療效，比較兩組的日常生活能力、美國國立衛(wèi)生研究院卒中量表（NIHSS）評分、血流動力學指標、血清炎性因子水平。結(jié)果 治療后，對照組總有效率為78.00%，治療組總有效率為96.00%，治療組顯著較高（P<0.05）。治療后，兩組Barthel指數(shù)評分顯著升高，NIHSS評分顯著降低（P<0.05），且治療組Barthel指數(shù)評分明顯高于對照組，NIHSS評分明顯低于對照組（P<0.05）。治療后，兩組患者全血高切黏度、全血低切黏度、血細胞比容、纖維蛋白原水平顯著降低（P<0.05）；并且治療組全血高切黏度、全血低切黏度、血細胞比容、纖維蛋白原水平明顯低于對照組（P<0.05）。治療后，兩組血清丙二醛（MDA）、高敏C反應蛋白（hs-CRP）、白細胞介素-6（IL-6）水平明顯降低（P<0.05）；并且治療組血清MDA、hs-CRP、IL-6水平明顯低于對照組（P<0.05）。結(jié)論 芪血通絡片聯(lián)合依達拉奉注射液治療急性腦梗死具有較好的療效，可以提高患者生活能力，改善血液流變學指標，降低血清炎性因子水平。

Objective To study the efficacy of Qixue Tongluo Tablets combined with Edaravone Injection in treatment of acute cerebral infarction. Methods Patients (100 cases) with acute cerebral infarction in Guangyuan Third People's Hospital from January 2019 to January 2020 were randomly divided into control and treatment groups, and each group had 50 cases. Patients in the control group were iv administered with Edaravone Injection, 30 mL/time, once daily. Patients in the treatment group were po administered with Qixue Tongluo Tablets on the basis of the control group, 4 tablets/time, three times daily. Patients in two groups were treated for 14 d. After treatment, the clinical efficacies were evaluated, and the ability of daily living, NIHSS score, hemodynamic indexes, and the serum inflammatory factors in two groups were compared. Results After treatment, the total effective rates in the control group and the treatment group were 78.00% and 96.00%, respectively, which was significantly higher than that in the control group (P<0.05). After treatment, Barthel Index score of two groups was significantly increased, but NIHSS score was significantly decreased (P<0.05), and the Barthel Index score of the treatment group was significantly higher than that of the control group, and NIHSS score was significantly lower than that of the control group (P<0.05). After treatment, the whole blood high shear viscosity, whole blood low shear viscosity, hematocrit, and fibrinogen levels of two groups were significantly decreased (P<0.05), and the whole blood high shear viscosity, whole blood low shear viscosity, hematocrit, fibrinogen levels in the treatment group were significantly lower than those in the control group (P<0.05). After treatment, serum levels of MDA, hs-CRP, and IL-6 in two groups were significantly decreased (P<0.05), and the serum levels of MDA, hs-CRP and IL-6 in the treatment group were significantly lower than those in the control group (P<0.05). Conclusion Qixue Tongluo Tablets combined with Edaravone Injection has clinical curative effect in treatment of acute cerebral infarction, can improve the living ability, improve hemorheology indexes, and reduce the serum level of inflammatory factors.

R971